メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・消化器内科学・第1
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(15)
研究成果
(542)
フィンガープリント
医学部・消化器内科学・第1が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Endoscopic Ultrasound
100%
Neoplasm
75%
Pancreas Cancer
50%
Narrow Band Imaging
48%
Hepatocellular Carcinoma
42%
Diagnosis
40%
Stomach Cancer
39%
Endoscopy
34%
Endoscopic Submucosal Dissection
34%
Helicobacter Pylori
34%
Endoscopic Ultrasound Guided Fine Needle Biopsy
29%
Malignant Neoplasm
29%
Pylorus
25%
Echography
24%
Gastrointestinal Stromal Tumor
24%
Colorectal Tumor
22%
Intraductal Papillary Mucinous Tumor
22%
Adenoma
22%
Fine-Needle Aspiration
21%
Pancreas Adenocarcinoma
17%
Pancreas Disease
17%
Disease
17%
Biliary Tract Drainage
16%
Cancer
15%
Overall Survival
15%
Lenvatinib
15%
Elastography
15%
Chronic Gastritis
15%
Bevacizumab
15%
Surgery
14%
Magnifying Endoscopy
14%
Immunoglobulin G4
14%
Metastatic Carcinoma
14%
Pancreas Tumor
14%
Polyp
13%
Jejunum Ulcer
13%
Arm
13%
Adverse Event
13%
Chronic Pancreatitis
13%
Ulcerative Colitis
12%
Confocal Laser Scanning Microscopy
12%
Promoter Region
11%
Stenosis
11%
Neuroendocrine Tumor
11%
Autoimmune Pancreatitis
11%
Multivariate Analysis
11%
Diagnostic Accuracy
11%
Differential Diagnosis
11%
Methylation
11%
Endoscopic Papillotomy
11%
Atezolizumab
11%
Hazard Ratio
11%
Symptom
11%
Sclerosing Cholangitis
11%
Computer Assisted Tomography
10%
Observational Study
10%
Upper Digestive Tract
10%
microRNA
10%
Colorectal Cancer
10%
Charlson Comorbidity Index
10%
Crohn's Disease
10%
Ultrasound Elastography
10%
Chronic Hepatitis C
10%
Diagnostic Performance
9%
Recurrent Disease
9%
Mucosa
9%
CpG Island
9%
Retrospective Study
9%
Stomach Mucosa
9%
White Light Endoscopy
9%
Cystic Pancreatic Lesion
9%
Systemic Therapy
9%
Scoring System
9%
Survival Rate
9%
Steroid Treatment
9%
Meta-Analysis
9%
Ras Signaling
9%
Pancreatic Duct
8%
Helicobacter Infection
8%
Cholestasis
8%
Biopsy
8%
Intestinal Metaplasia
8%
Liver Cirrhosis
8%
Histology
8%
Transcatheter Arterial Chemoembolization
8%
Ulcer
8%
Hematemesis
8%
Esophagus
8%
Cholangiocarcinoma
8%
Perfluorobutane
8%
Pancreatitis
7%
Duodenum
7%
Biliary Tract Disease
7%
Biliary Duct Cancer
7%
Systematic Review
7%
Stomach Ulcer
7%
Carcinoma
7%
Choledochoduodenostomy
7%
Diagnostic Procedure
7%
Prognostic Factor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Stomach Cancer
81%
Liver Cell Carcinoma
62%
Chemotherapy
42%
Bevacizumab
32%
Disease
30%
Malignant Neoplasm
28%
Adverse Event
26%
Atezolizumab
24%
Helicobacter Pylori
24%
Overall Survival
23%
Pancreas Cancer
23%
Neoplasm
19%
Adenoma
18%
Progression Free Survival
17%
Jejunum Ulcer
16%
Cisplatin
14%
Sunitinib
14%
Colorectal Tumor
14%
Duodenum Ulcer
14%
Stomach Ulcer
14%
Nonalcoholic Fatty Liver
14%
Ulcer
13%
Lenvatinib
13%
Clinical Trial
12%
Helicobacter Infection
12%
Colorectal Cancer
12%
Capecitabine
12%
Crohn's Disease
11%
Imatinib
10%
Gastrointestinal Stromal Tumor
10%
Observational Study
10%
Intestine Metaplasia
10%
Ramucirumab
10%
Placebo
10%
Toll Like Receptor 4
9%
Carcinogenesis
9%
Irinotecan
9%
Metastatic Colorectal Cancer
8%
Sorafenib
8%
Comorbidity
8%
Gastric Mucosa
8%
Metaplasia
8%
Combination Therapy
8%
Gamma Urogastrone
8%
Transcription Factor Nrf2
7%
Paclitaxel
7%
Trastuzumab
7%
Fluoropyrimidine
7%
Precancer
7%
Atrophic Gastritis
7%
Pancreas Adenocarcinoma
7%
Retrospective Study
7%
Gastritis
7%
Ulcerative Colitis
7%
microRNA
7%
Sclerosing Cholangitis
7%
RANTES
7%
Immunotherapy
7%
Zoledronic Acid
7%
Pancreas Islet Cell Tumor
7%
Recurrent Disease
7%
Neutropenia
7%
Polyp
6%
Alpha Fetoprotein
6%
Biological Marker
6%
Aspartate Aminotransferase
6%
Liver Cirrhosis
6%
Hepatitis B Antigen
6%
Intestine Flora
6%
Chronic Hepatitis C
6%
Omeprazole
6%
Phospholipase
6%
Infection
5%
Chronic Gastritis
5%
Non-Steroidal Anti-Inflammatory Drug
5%
Adenocarcinoma
5%
C Reactive Protein
5%
Fluorouracil
5%
Inflammation
5%
Survival Rate
5%
Oxaliplatin
5%
Prospective Study
5%
Keyphrases
Polymorphism
23%
Atezolizumab Plus Bevacizumab
22%
Advanced Hepatocellular Carcinoma
22%
Helicobacter Pylori (H. pylori)
22%
Gastroduodenal Diseases
16%
Gastric Cancer
16%
Intestinal Metaplasia
15%
Japan
15%
Genotype
14%
Ulcerative Colitis
14%
Gastric mucosal Atrophy
13%
Chronic Gastritis
13%
Gastric mucosa
12%
Genetic Polymorphism
11%
Intraductal Papillary mucinous Neoplasm
11%
Endoscopic Ultrasound
11%
Advanced Gastric Cancer
11%
Gastrointestinal Stromal Tumor
11%
Lenvatinib
11%
Chemotherapy
11%
Pancreatic Cancer
10%
Functional Dyspepsia
10%
Pre-microRNA
10%
Gastritis
10%
Helicobacter Pylori Eradication
10%
Gene Polymorphism
10%
CpG Island Methylation
10%
Odds Ratio
9%
Japanese Population
8%
Interleukin-17 (IL-17)
8%
Pancreatic Neuroendocrine Tumors (pNETs)
8%
Differential Diagnosis
8%
Methylation Status
8%
Endoscopic Ultrasonography
8%
Clinical Outcomes
8%
Adverse Events
7%
NADPH Oxidase
7%
Receptor 2
7%
Toll-like
7%
Non-neoplastic
7%
Gastric Cancer Patients
7%
Helicobacter Pylori Infection
7%
Gastric mucosal
7%
Macrophage Migration Inhibitory Factor
7%
Pharmacologic Conversion
7%
Pro-tumor
7%
REG4
7%
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD)
7%
Endoscopic Ultrasound-guided Choledochoduodenostomy
7%
Toll-like Receptor 4 (TLR4)
7%
RANTES
7%
3′-untranslated Region (3′-UTR)
7%
N-score
7%
Magnifying Narrow-band Imaging
7%
Endoscopic Submucosal Dissection
7%
Common Genetic Variants
7%
Nrf2 Gene
7%
Japanese Subjects
7%
Solid Pseudopapillary Tumor
7%
Endoscopic Features
7%
Ramucirumab
7%
IgG4-related Sclerosing Cholangitis
7%
Combination Therapy
7%
Rs3746444
7%
Updated Sydney System
7%
Duodenal Ulcer
6%
Atrophy
6%
Toll-like Receptor 2 (TLR2)
6%
Liver Function
5%
Aspirin Use
5%
Gastric Ulcer
5%
Rs11614913
5%
Microvascular Invasion
5%
Confidence Interval
5%
Female Subjects
5%
Promoter Polymorphism
5%
Docetaxel
5%
Periampullary Cancer
5%
Narrow-band Imaging Endoscopy
5%
MiR-146a rs2910164
5%
Hepatocellular Carcinoma
5%
Overall Survival
5%
Magnifying Endoscopy with Narrow-band Imaging
5%
Tumor
5%
Unresectable Hepatocellular Carcinoma
5%
Non-cancer
5%
Antral Biopsy
5%
Worrisome Features
5%
CDH1 Methylation
5%